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Background: Obesity is a risk factor for self-reported asthma and makes asthma management
more difficult. The effects of bariatric surgery on asthma in severely obese subjects remain to
be documented.
Methods: In this prospective study, 12 asthmatic patients with severe obesity were evaluated
before, 6 and 12 months after bariatric surgery. Each had methacholine inhalation tests,
measures of expiratory flows and lung volumes, measurements of C-reactive protein and ques-
tionnaires on asthma medication, asthma symptoms and co-morbid conditions. Eleven severely
obese patients with asthma (considered as controls) underwent the same evaluations. Primary
endpoint was airway responsiveness to methacholine and secondary endpoints were lung
volumes and markers of systemic inflammation.
Results: Mean body mass index decreased from 51.2 to 34.4 kg/m2 twelve months post-surgery.
Mean PC20 methacholine improved from 0.84 to 6.2 mg/ml (P < 0.001); FEV1, FVC, FRC, FRC/
TLC and ERV all improved (P  0.006). C-reactive protein decreased from 8.6 to 1.7 mg/L
(P < 0.001) Asthma symptoms total score was significantly reduced (P Z 0.03) and asthma
medication needs decreased, ten patients being able to stop all asthma drugs. No significant
changes of these parameters from baseline were observed in asthmatic controls. Improve-
ments in airway responsiveness and lung volumes happened in parallel and correlated with
reductions of body mass index (r Z 0.58, P Z 0.049), C-reactive protein levels (r Z 0.74,
P Z 0.004).
Conclusion: Airway responsiveness, lung volumes and asthma severity/control markedly
improved with weight loss following bariatric surgery in severely obese patients.
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Obesity is responsible for a large morbidity and mortality
worldwide.1 Obesity can contribute to the development of
many chronic diseases and has been considered as
a contributing factor to the development of asthma.2e4 In
a meta-analysis reported by Beuther et al., odds ratio of
incident asthma after one year of follow-up in obese (Body
Mass Index (BMI) 30 kg/m2) versus normal-weight individ-
uals (BMI<25 kg/m2) was 1.92 (P < 0.001).5 Severe obesity
(BMI40 kg/m2), is associatedwith a very high prevalence of
asthma, altered pulmonary function, poor asthma treatment
response and high morbidity.1,5,6 Patients with severe
obesity are more likely to suffer from co-morbid conditions
and their asthma is difficult to manage.7,8 Finally, obesity is
associated with an increase in systemic inflammation as re-
flected by increased levels of C-reactive protein (CRP).9
Asthma control can improve in non-severe asthma after
moderate weight loss, but the effects of marked weight loss
on lung function and airway responsiveness remain uncer-
tain.10,11 In severely obese patients, bariatric surgery is
considered as an option to induce a significant weight loss,
particularly when it is associated with significant co-morbid
conditions.3,12 In a previous retrospective analysis, we
showed, as others, that after bariatric surgery, obese
asthmatics had a marked reduction in self-reported severity
of asthma over a 2-year period although pulmonary func-
tion was not recorded.13
This study was performed to investigate the impact of
a biliopancreatic diversion with duodenal switch proce-
dure14 on the changes in airway responsiveness, lung
function and asthma control in severely obese asthmatic
patients at baseline, then 6 and 12 months after surgery
compared with controls. We also compared these changes
with markers of systemic inflammation.
Methods
Selection of participants
Twenty-three subjects (intervention group: 12, control
group: 11) with a diagnosis of asthma based on the Amer-
ican Thoracic Society (ATS) criteria15 were enrolled.
Inclusion and exclusion criteria
Inclusion criteria were: asthmatic patients 18 years old
with severe obesity, defined by a BMI>40 kg/m2, or35 kg/
m2 with existing co-morbidity. Exclusion criteria were:
previous vagotomy or bariatric surgery, cognitive limitations
not allowing filling the questionnaire appropriately, unstable
asthma, recent (<1 month) asthma exacerbation, or any
health problem interfering with the evaluation.
The study was approved by our local Ethics Committee
(CER20086). All patients signed an informed consent form.
Study design and evaluation
This is a one-year prospective controlled parallel group
study in severely obese patients with asthma.Atopic status
At baseline, the subjects’ atopic status was confirmed with
an allergy skin prick test performed with common airborne
allergens.
The following evaluations were done at the baseline, 6-
month and one-year visits:
Demographics
Patients were weighted and BMI calculated. Waist circum-
ference was measured at the uppermost part of the iliac
crest and hip circumference at its widest part.
Methacholine test and lung volumes
Methacholine inhalation tests were performed according to
the ATS criteria,16 using Knudson predicted values.17 Meth-
acholine was administered18 using the 2-min tidal breathing
method, up to a concentration of 16 mg/ml; results were
expressed as the provocative concentration ofmethacholine
inducing a 20% fall in forced expiratory volume in 1 s (PC20
FEV1). Changes in airway responsiveness were expressed in
number of doubling concentrations of methacholine.19 Lung
volumes were obtained by body plethysmography.20
Blood sampling
A blood sample was drawn after a 12h overnight fast for
differential cell count and measurement of high sensitive C-
reactive protein (hs-CRP). Hs-CRP levels were measured
with an immunoturbidimetric method, using a Roche Diag-
nostics Integra 800 System.21
Questionnaires
All subjects filled a standardized respiratory questionnaire
based on the European Community Respiratory Health
Survey questionnaire.22 The validated Asthma Control
Questionnaire (ACQ) evaluated the degree of asthma
control during the week preceding visits.23
Outcomes
The primary endpoint was the change in airway respon-
siveness following bariatric surgery. Secondary endpoints
included changes in: (a) lung volumes, (b) measures of
blood inflammation markers, neutrophils and eosinophils
counts and hs-CRP levels; (c) asthma medication use; and
(d) scores on ACQ.
Statistical analysis
It was assumed that a mean improvement in airway
responsiveness of one doubling concentration of meth-
acholine compared with baseline was clinically significant.
Based on a study by Inman et al., with an average shift of
4.11 doubling concentrations after bronchodilator treat-
ment and a SD Z 1.08, we anticipated that 12 subjects in
the group undergoing bariatric surgery should be sufficient
to observe significant changes in airway responsiveness
with 90% power and an a error <5%.24
Bariatric surgery, airway response, lung function 653Results are expressed as mean  SD. For statistical
analysis, a PC20 >16 mg/ml was considered equal to 16 mg/
ml and analyzed using a Cox model. Data not normally
distributed were log transformed before analysis. A one-
factor repeated measures ANOVA analysis was performed
for the various parameters to follow patients before and
after surgery. For comparisons with the control group, two-
factors repeated measures ANOVA analysis was used.
Correlations between changes pre- and post-surgery were
done using linear regression analysis. A P value <0.05 was
considered significant. Analyses were conducted using the
statistical package SAS, version 9.2 (SAS Institute Inc., Cary,
NC, U.S.A.).Results
In a group of 73 patients offered bariatric surgery for severe
obesity, 24 agreed to participate in the study (Fig. 1).
Twelve had proven asthma and were enrolled. Of the last 45
patients in the waiting list for surgery (controls), 14
declined to participate, 31 were interested by the respi-
ratory evaluation proposed but 8 had an advanced scheduleAssessed for eligibility (n=24)
Subjects scheduled for a 
bariatric surgery (n= 73)
No diagnosis of asthma 
(n=12)
Enrolled (n=12)
Intervention group
6-month follow-up (n=12)
One -year follow-up (n=10)
Intervention group
n = 12 Baseline
n = 12 6-month follow-up
n = 10 One-year follow-up
Lost to follow-up
Lack of time (n=2)
Declined to participate: 
(n=49)
Figure 1 Flofor bariatric surgery. Of the 23 remaining patients, 12 had
asthma and were recruited. One patient (control group)
was excluded due to non-compliance to the visits. During
the follow-up, 2 treated asthmatics quit the study after the
6-month visit and one control had bariatric surgery after
the 6-month visit.
Subjects’ characteristics are summarized in Table 1. The
intervention group included 9 women and 3 men (41  10
years) and the control group, 8 women and 3 men (44  11
years, PZ 0.62). Mean BMI was respectively 51.2  7.3 kg/
m2 and 45.7  10.4 (P Z 0.15). The intervention group
included 4 non-smokers, 4 ex-smokers (mean: 21.6 pack-
year, mean smoking cessation: 9.5 years) and 4 smokers
(mean: 12.8 pack-year) and the control group 5 non-
smokers, 3 ex-smokers (mean: 17 pack-year, mean
smoking cessation: 22.7years) and 3 smokers (mean: 14.2
pack-year). At baseline, all patients of the intervention
group and 10 of the control group used asthma medication
(Table 2). Five patients in the intervention group and 7 in
the control group were atopic and respectively, 6 and 7
patients presented features of the metabolic syndrome
according to the criteria of the Diabetes International
Federation defined as the existence of at least three of theSubjects on the far end of 
waiting list for bariatric surgery
(n= 45)
Declined to participate: 
(n=14)
Scheduled for bariatric
surgery (n=8)
No diagnosis of asthma
(n=11)
Non compliance to tests 
(n=1)
Lost to follow-up
Scheduled for 
bariatric surgery 
(n=1)
Control group (no surgery)
n = 11
n = 11
n = 10
Enrolled (n=11)
Control group
6-month follow-up (n=11)
One-year follow-up (n=10)
Assessed for eligibility (n=31)
w diagram.
Table 1 Subjects’ characteristics at baseline.
# Sex Age BMI FEV1 %
a Asthma onset (age) Co-morbidities Atopy Metabolic
syndrome
Study group (bariatric surgery)
1 F 36 57 95 36 HBP No Yes
2 F 50 46 86 12 Diabetes No No
3 M 42 39 76 34 HBP, high cholesterol No Yes
4 F 42 42 92 23 Hypothyroidism Yes No
5 F 45 49 93 26 HBP, diabetes, GERD Yes Yes
6 F 44 52 90 0 HBP, diabetes No Yes
7 F 21 65 106 5 Yes No
8 F 52 50 91 1 Hypothyroidism No No
9 F 30 53 119 21 No No
10 F 59 50 98 2 HBP, diabetes Yes Yes
11 M 39 60 86 38 HBP, GERD No Yes
12 M 36 53 69 14 Sleep apnea Yes No
Control group (on waiting list for bariatric surgery)
1 F 38 48 70 29 HBP, diabetes Yes Yes
2 F 53 39 77 45 HBP, high cholesterol Yes Yes
3 F 48 43 81 40 HBP, sleep apnea, heart disease No Yes
4 F 44 44 84 25 No No
5 F 54 43 80 53 HBP, high cholesterol Yes Yes
6 M 47 35 84 30 HBP, high cholesterol Yes Yes
7 F 31 39 60 20 Depression, hyperthyroidism Yes No
8 F 61 36 84 61 No No
9 M 38 69 77 0 HBP, high cholesterol No Yes
10 M 21 60 83 20 HBP, high cholesterol,
diabetes, GERD, OSA
Yes Yes
11 F 44 46 106 29 Pneumonia Yes No
HBP: high blood pressure, GERD: gastroesophageal reflux disease, OSA: obstructive sleep apnea.
a Percent of predicted values.
654 L.-P. Boulet et al.following criteria: increased waist circumference (102 cm
in men, >88 cm in women), high fasting plasma glucose
(>5.6 mmol/L) or diagnosis of type 2 diabetes, high blood
pressure (130/85 mm Hg) or treatment for hypertension,
increased triglycerides (1.7 mmol/L), reduced HDL-
cholesterol (1.03 mmol/l in men, 1.29 in women) or
specific treatment for this abnormality.25
Obesity parameters
Bariatric surgery induced a significant reduction in BMI,
waist and hips circumference (Table 3, P < 0.001). No
significant changes were observed in control group.
Evolution of parameters over time
Weight loss, improvements of airway responsiveness and
lung function, reduction of asthma symptoms and asthma
medication use occurred mostly within the 6 months
following bariatric surgery (Tables 2 and 3); improvements
were still observed between 6 months and one year but
were less important and not significantly different from
those measured after 6 months.
Baseline and post-surgery changes in airway response to
methacholine, lung function and hs-CRP levels in the
intervention group were similar in patients with or withoutthe metabolic syndrome and in atopic and non-atopic
patients.
Airway responsiveness to methacholine
At baseline, PC20 methacholine ranged from 0.1 to 12 mg/
ml in the intervention group and from 0.16 to 16 mg/ml in
the control group (P > 0.05). The two patients with a PC20
16 mg/ml used combined LABA/ICS medication for asthma
control and had previous confirmation of asthma diagnosis.
In the intervention group, PC20 methacholine improved by
a mean of 2.4 and 2.7 doubling concentrations, respec-
tively, 6 and 12 months post-surgery (P < 0.001) while it
remained stable (PZ 0.49) in the control group. There was
no difference in improvement in airway responsiveness
whether the patients were atopic (Fig. 2A) or not or had the
metabolic syndrome or not (Fig. 2B).
Lung volumes
Lung volumes are summarized in Table 3. Baseline FEV1 was
under 80% of predicted values in two patients of the
intervention group (69% and 76%) and 4 of the control group
(60%, 70%, 77% and 77%); the ratio FEV1/FVC was >70% in all
patients. However, patients significantly improved their
FEV1, forced vital capacity (FVC), functional residual
Table 2 Subjects’asthma daily medication.
Baseline 6 months One year
Patients who underwent bariatric surgery
1 s-a bd 200 mg None None
2 s-a bd 200 mg None None
3 s-a bd prn None None
4 s-a bd 200 mg None None
5 s-a bd 400 mg, ICS: 500 mg s-a bd prn, ICS: 500 mg s-a bd prn
6 s-a bd 400 mg, l-a bd: Sp 18 mg,
ICS: 1200 mg bd/ICS: 500 mg
s-a bd prn, l-a bd: Se(100 mg),
ICS: 1000 mg
None
7 bd/ICS: 1000 mg Same as baseline Same as baseline
8 s-a bd (prn), ICS: 500 mg None None
9 s-a bd (prn) None None
10 s-a bd 200 mg, ICS: 1000 mg s-a bd prn None
11 s-a bd 200 mg None None
12 s-a bd prn None None
Patients on waiting list for bariatric surgery (control group)
1 s-a bd: 200 mg, ICS: 500 mg Same as baseline Same as baseline
2 s-a bd prn Same as baseline Same as baseline
3 s-a bd 400 mg ICS: 500 mg,
(bd/ICS: 750 mg allergy period)
Same as baseline Same as baseline
4 None None None
5 s-a bd 700 mg Same as baseline Same as baseline
6 s-a bd prn, ICS: 1000 mg Same as baseline Same as baseline
7 s-a bd 200 mg, ICS: 500 mg Same as baseline Same as baseline
8 s-a bd prn Same as baseline Same as baseline
9 s-a bd 400 mg, l-a bd: Sp 18 mg, ICS: 400 mg Same as baseline Same as baseline
10 s-a bd 200 mg, bd/ICS: 500 mg s-a bd prn, bd/ICS: 500 mg N/Aa
11 s-a bd 200 mg, ICS: 500 mg, bd/ICS: 500 mg Same as baseline Same as baseline
s-a bd: short-acting inhaled bronchodilators (in equivalent of salbutamol), l-a bd: long-acting inhaled bronchodilators (Sp Z spiriva,
SeZ serevent), ICS: inhaled corticosteroids (in equivalent of fluticasone), bd/ICS: combined medication (in equivalent of fluticasone).
a The subject had bariatric surgery between the 6-month and the one-year periods.
Table 3 Parameters measurements during the study.a
Intervention group Control group
Baseline 6 months One year ANOVA P Baseline 6 months One year ANOVA P
Waist (cm) 141  25 104  35 107  13 <0.001 123  18 128  22 117  13 0.09
Hips (cm) 155  18 125  10 120  10 <0.001 141  20 143  20 138  19 0.26
Weight (kg) 142  33 105  21 91  18 <0.001 127  41 126  42 117  32 0.80
BMI (kg/m2) 51.2  7.3 38.4  5.5 34.4  4.3 <0.001 45.7  10.4 45.5  10.9 43.4  9.3 0.81
PC20 (mg/ml) 0.84
(0.01e12)
4.53
(0.39e16)
6.24
(0.33e16)
<0.001 2.62
(0.16e16)
4.07
(0.59e16)
4.37
(0.51e16)
0.49
FVCb 97  18 114  15 119  12 <0.001 98  17 95  16 97  15 0.18
FEV1
b 95  15 105  11 106  10 <0.001 83  16 81  13 85  14 0.83
FEV1/FVC
b 96  7 93  10 94  7 0.13 90  9 91  8 96  10 0.01
FEF25e75
b 75  23 83  15 87  28 0.43 78  23 79  22 80  17 0.86
TLCb 105  15 112  13 111  13 0.10 101  11 104  12 100  12 0.26
RVb 109  17 109  32 94  21 0.68 110  27 120  25 109  19 0.47
FRCb 84  9 103  18 102  9 <0.001 85  14 88  18 86  12 0.50
FRC/TLCb 0.82  0.13 0.93  0.24 0.93  0.10 0.003 0.84  0.11 0.85  0.14 0.87  0.11 0.99
VCb 105  18 118  14 123  11 <0.001 102  20 101  17 101  15 0.23
ERVb 54  39 86  48 116  24 0.006 46  21 33  21 44  13 0.50
PC20: provocative concentration of methacholine inducing a 20% fall of FEV1. FVC: forced vital capacity, FEV1: forced expiratory volume
in 1 s, FEV1/FVC: ratio of forced vital capacity/forced expiratory volume in 1 s, FEF 25e75: mid forced expiratory flow (25e75%), TLC:
total lung capacity, RV: residual volume, FRC: functional residual capacity, FRC/TLC: ratio of forced vital capacity/total lung capacity,
VC: vital capacity, ERV: expiratory reserve volume.
a Mean  SD; mean (range) for methacholine PC20.
b Expressed in percent of predicted values.
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Figure 2 Change in airway responsiveness in number of double concentrations of methacholine after bariatric surgery in patients
with or without (A) atopy (B) metabolic syndrome.
656 L.-P. Boulet et al.capacity FRC, ratio FRC/Total Lung Capacity (TLC), vital
capacity (VC) and expiratory reserve volume (ERV)
compared to baseline (FEV1 and ERV shown with PC20
improvement, Fig. 3). These parameters remained stable in
the control group.
Measures of systemic inflammation
Blood eosinophils (intervention group: 2.4  1.6%, control
group 2.6  1.0%) and neutrophil counts (respectively,
64  9% and 66  7%) were similar in both groups andOne year
post-op
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Figure 3 Improvement in lung volumes: (shown) FEV1
(P < 0.001), ERV (P Z 0.006) and in airway responsiveness
(P < 0.001) during the year following bariatric surgery.remained unchanged post-surgery. Levels of hs-CRP
decreased significantly (baseline, 6 and 12 months:
8.6  6.3, 4.3  5.1 and 1.7  2.2 mg/L, P < 0.001) while no
significant change was observed in the control group
(respectively: 10.1  6.8, 10.9  9.8 and 7.8  6.3 mg/L,
P Z 0.67).
Asthma medication
Six months following bariatric surgery; 8 patients were able
to stop inhaled bronchodilators and 2 their inhaled corti-
costeroids (ICS) (Table 2). After 12 months, only two
patients, both atopic, were still using asthma medication
(one, a short-acting b-2 agonist on demand and one,
a combined medication). In the control group, medication
use remained unchanged throughout the study.
ACQ questionnaire
The ACQ showed a progressive improvement in scores after
surgery compared to baseline for asthma night awakening,
morning symptoms, activity limitation and dyspnea,
(p < 0.05, Table 4). Scores for wheeze (P Z 0.004) and
number of inhalations of short-acting b-2 agonist/day
(P Z 0.03) were significantly reduced. The asthma total
score, obtained by adding scores of the 6 items of the
questionnaire was significantly reduced post-surgery
(P Z 0.03). There were no significant differences
between answers to the ACQ in the control group.
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Bariatric surgery, airway response, lung function 657Relationships between changes in airway
responsiveness, BMI, hs-CRP and lung volumes
Improvement in airway responsiveness 6 months post-
surgery correlated significantly with the reduction of BMI
(rZ 0.58, PZ 0.049) and of hs-CRP(rZ 0.74, PZ 0.004,
Fig. 4A and B). Although airway responsiveness correlated
with FRC (rZ 0.40, PZ 0.02) and ERV (rZ 0.36, PZ 0.02
Fig. 4C and D), at all study time-points, improvements in
airway responsiveness were not significantly correlated
with changes in FRC (r Z 0.30, P Z 0.40, not shown), ERV
(r Z 0.38, P Z 0.25, Fig. 4E) or other lung volumes (all
P > 0.05). No significant correlation was found between the
change in airway responsiveness after surgery and the age
at onset of asthma (rZ 0.33, PZ 0.92) or the duration of
asthma (r Z 0.12, P Z 0.71). Furthermore, the decrease
in hs-CRP did not correlate significantly with the reduction
in BMI (r Z 0.33, P Z 0.29) or the reduction in centi-
meters of waist circumference (r Z 0.53, P Z 0.11)
although it correlated significantly with improvements in
ERV (r Z 0.61, P Z 0.05, Fig. 4F).
Discussion
In this study, weight loss in severely obese asthma patients
following bariatric surgery was associated with a significant
reduction in airway responsiveness to methacholine, an
improvement in lung function, a reduction in asthma
medication and better asthma control. Reduction of BMI
and improvement in airway responsiveness correlated with
the reduction in hs-CRP, a marker of airway inflammation.26
In the general population of obese subjects, reductions in
weight up to 23% have been associated to improvements of
asthma control parameters, including FEV1, FVC and
reduced medication needs11,27 while surgery in the most
severe forms of obesity brought the most remarkable
results, in addition to improvements in associated co-
morbidities.3,10,12,13,28 Most studies involving obesity
surgery in asthma patients only evaluated its effects on the
improvement of asthma symptoms and reduction in medi-
cation use.29,30
In non-asthmatic subjects, obesity did not influence
breathlessness or airway response to methacholine
although lung volumes such as FRC and ERV were reduced.31
Airway hyperresponsiveness has been positively associated
with FRC and, in men, potentially increasing with a reduc-
tion in lung volumes.32 Although FRC and ERV improved in
asthma subjects following bariatric surgery, the changes in
these lung volumes correlated, although not significantly,
with the improvements observed in airway responsiveness
during the same period. This could suggest that the changes
in airway responsiveness could have been influenced by
lung volume changes but the lack of statistical significance
seems to indicate that this was not the sole factor. Obesity-
related increased stiffness of the chest wall affects its
outward recoil and leads to a reduction in FRC, conse-
quently obese patients breathe at low volumes. Low
volume breathing has an effect in reducing the stretch of
the airway smooth muscle that becomes stiffer ensuing
increased shortening and leading to airway narrowing. We
previously demonstrated in normal lean subjects that
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Figure 4 Correlations of the change in airway response to methacholine with (A) BMI reduction and (B) change in hs-CRP.
Correlations between airway responsiveness and (C) FRC and (D) ERV. Correlations between changes in airway response to
methacholine with (E) the change in ERV. Correlations between change in % predicted ERV and (F) change in hs-C-reactive protein
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658 L.-P. Boulet et al.a 20 min period of deep inspiration avoidance before
methacholine challenge increased airway responsiveness.33
Mechanical decreases in lung volumes in non-asthmatic
subjects, induced by simulated obesity, either by external
chest loading, lower limb compression or both, have also
been shown to increase airway responsiveness; a dos-
eeresponse relationship was observed between the degree
of simulated obesity and airway responsiveness.34
Airway responsiveness improved significantly and asthma
medication needs were significantly reduced in our asthma
patients following surgery independently of atopic status or
presence or absence of a metabolic syndrome. Recently,
Dixon et al. observed a significant improvement in airway
hyperresponsiveness (AHR) 12 months after gastric bypass
surgery, subjects with normal IgE levels before surgery
having significantly higher improvements in AHR than those
with high IgE levels.35In another study, Aaron et al. reported amodest influence
of diet-induced weight loss on airway responsiveness, in
a group of 56 women of which 24 had asthma, observing no
change in asthma medication during the 6-month study
period.11 The apparent difference between these results and
ours could be due to the less important weight loss following
diet (20 kg) compared with bariatric surgery (37 kg).
We found no evidence of residual airway obstruction
before surgery. In this regard, Sin et al. previously observed
that a lack of airflow obstruction was more frequent in
obese than non-obese patients using bronchodilators.36 This
could indicate that asthma symptoms, such as dyspnea and
wheeze, could be the consequence of factors related to
obesity instead of airflow limitation. However, FEV1, FVC,
FRC and ERV significantly improved following bariatric
surgery and were accompanied by decreased asthma
symptoms, confirming previous observations on obesity
Bariatric surgery, airway response, lung function 659surgery or diet-induced weight loss.11,27,28,35 Changes in
lung volumes did not correlate significantly with changes in
PC20 methacholine. In this regard, breathing at low volume
could theoretically promote airway responsiveness in
modifying airway smooth muscle elasticity.37,38 We previ-
ously showed that airway response to deep breathing was
abnormal in obese subjects, being similar to asthmatic
subjects.33,39 Therefore, such improvement in ERV could
have contributed to a reduction in airway responsiveness
although it may not be the sole factor.
An elevated CRP has been associated with an acceler-
ated decline in lung function independent of BMI and
asthma.40 Furthermore, increases in pro-inflammatory
adipokines such as leptin have been associated with
asthma in children and with airway responsiveness in
animal models.41,42 Increased CRP levels and sputum
neutrophilic airway inflammation have recently been
observed in obese women with asthma.43 but previous
studies have suggested that systemic inflammation could
not explain the links between asthma and obesity.44
Furthermore, Todd et al. found no association between
BMI and airway inflammation in a group of over 700 asth-
matic and non-asthmatic patients measured by induced
sputum.45 In our study, hs-CRP was significantly reduced
after bariatric surgery in asthma patients and correlated
with improvements in airway responsiveness although it
may only be related to weight loss.
The strengths of our study include measures of airway
responsiveness, lung function, and hs-CRP marker of airway
inflammation, and assessment of asthma medication use
and asthma control before and after weight loss following
bariatric surgery. A limitation to our study is the small
sample size. We believe that our observations are impor-
tant for the management of asthma in the obese, suggest-
ing that weight loss should be a primary target therapy of
these patients.
In summary, significant improvements in lung function
and airway responsiveness were observed in asthma
patients following biliopancreatic diversion with duodenal
switch; these changes correlated significantly with the
reduction of the hs-CRP systemic inflammatory marker.
Asthma medication use and asthma symptoms decreased
significantly. The mechanisms underlying these changes
remain to be determined.
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